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Abstract
Background: We previously observed the over-expression of BMP-2 in primary cultures of
epithelial ovarian cancer (EOC) cells as compared to normal epithelial cells based on Affymetrix
microarray profiling [1]. Here we investigate the effect of BMP-2 on several parameters of ovarian
cancer tumorigenesis using the TOV-2223, TOV-1946 and TOV-112D EOC cell lines.
Methods:  We treated each EOC cell line with recombinant BMP-2 and assayed various
parameters associated with tumorigenesis. More specifically, cell signaling events induced by BMP-
2 treatment were investigated by western-blot using anti-phosphospecific antibodies. Induction of
Id1, Snail and Smad6 mRNA expression was investigated by real time RT-PCR. The ability of cells
to migrate was tested using the scratch assay. Cell-cell adhesion was analyzed by the ability of cells
to form spheroids. We also investigated BMP-2 expression in tissue samples from a series of EOC
patients.
Results: Treatment of these cell lines with recombinant BMP-2 induced a rapid phosphorylation
of Smad1/5/8 and Erk MAPKs. Increased expression of Id1, Smad6 and Snail mRNAs was also
observed. Only in the TOV-2223 cell line were these signaling events accompanied by an alteration
in cell proliferation. We also observed that BMP-2 efficiently increased the motility of all three cell
lines. In contrast, BMP-2 treatment decreased the ability of TOV-1946 and TOV-112D cell lines to
form spheroids indicating an inhibition of cell-cell adhesion. The expression of BMP-2 in tumor
tissues from patients was inversely correlated with survival.
Conclusion: These results suggest that EOC cell secretion of BMP-2 in the tumor environment
contributes to a modification of tumor cell behavior through a change in motility and adherence.
We also show that BMP-2 expression in tumor tissues is associated with a poorer prognosis for
ovarian cancer patients.
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Background
Epithelial ovarian cancer (EOC) is the second most com-
mon gynecological cancer and accounts for nearly half of
all deaths associated with gynecological pelvic malignan-
cies. Largely asymptomatic, over 70% of patients diag-
nosed with ovarian cancer at an advanced stage of the
disease. Early detection is rare and screening programs in
the general population have been unsuccessful. Recent
studies have analyzed gene expression patterns to identify
the molecular events involved in the development of can-
cer and to uncover diagnostic and prognostic markers.
This approach, applied to ovarian cancer [2-10], has
resulted in the identification of several hundred genes dif-
ferentially expressed between NOSE (normal ovarian sur-
face epithelia) and EOC [11]. In a previous study from our
group [1] several candidate genes that discriminate NOSE
from EOC cells were identified and validated by real time
RT-PCR. The differential expression of one of these candi-
dates, bone morphogenic protein-2 (BMP-2), was further
validated by immunohistochemistry (IHC) of patient tis-
sue samples [1].
The biological role of BMP-2 in ovarian cancer has not
been elucidated. BMPs are members of the TGF-β super-
family, which play an important role in embryonic devel-
opment events, such as gastrulation, neurogenesis,
hematopoiesis and apoptosis [12,13]. Recent studies have
suggested that some BMPs are implicated in cancer devel-
opment [14] as shown in breast and prostate cancer
(reviewed in [15,16]). The effects of BMP-2 on cancer cells
are controversial and are perhaps dependent on the tissue
and environment where they are expressed [17]. For
example, BMP-2 has been shown to stimulate the growth
of pancreatic carcinoma cells and prostate cancer cells in
absence of androgen [18,19]. On the other hand, BMP-2
clearly inhibits the growth of tumor cells of many origins
including cancers arising from thyroid, androgen-depend-
ent prostate in presence of androgen, myeloma, gastric
and pancreatic cells [14,18-22]. In cancer cells, BMP-2 was
found to suppress apoptosis induced by TNFα or by
serum deprivation [23-25]. In ovarian cancer, overexpres-
sion of BMP-2, BMP-4 and BMP-7 mRNAs have been
reported as dysregulated by microarray analyses [1,7,8]. A
recent study has demonstrated the involvement of BMP-4
in the epithelial mesenchymal transition in human ovar-
ian cancer cells [26]. Since BMP-2, along with family
members BMP-4 and BMP-7, share the same receptors
they may have similar effects. However, the binding affin-
ity of BMPs on these receptors and subsequent receptor
oligomerization are different which may lead to different
downstream signaling and biological effects in response
to BMPs [15,27].
BMP-2 acts via two types of serine/threonine receptors
[27]. Type I receptors are BMPR1a/Alk3 and BMPR1b/
Alk6 and type II receptors are BMPR2 and ActRIIA. Type I
receptors are phosphorylated by type II receptors after oli-
gomerization occurs. Of the two signaling pathways for
BMP, the Smad-dependent pathway appears to be the
most important. Smad 1/5/8 are mediators of BMPRIa
and BMPRIb whereas Smad6 and Smad7 are the inhibi-
tory Smads of this pathway [28] Phosphorylated Smad 1/
5/8 forms a complex with Smad4 and translocate in the
nucleus (review [15]). The Smad-independent pathway
activates TAK1, which can lead to MAPK activation as well
as Akt and NF-kappaB activation [29,30]. The most char-
acterized target genes of the BMP-2 signaling are Id1 and
Smad6 that encode products promoting the growth regu-
lation of BMPs. The signaling pathway induced by BMP-2
can be modulated by numerous antagonist proteins, such
as Noggin, Cerbarus and Gremlin. These antagonists are
secreted in the extracellular matrix. Previous results using
Noggin [26] and Chordin [31] support the potential ther-
apeutic role of these antagonists in ovarian cancer pro-
gression through the inhibition of BMP signaling. It has
also been reported that Gremlin gene expression is lower
in ovarian cancer specimens compared to normal ovarian
culture [28].
In the present study, we focused on the role of BMP-2 in
ovarian cancer. First, we examined the biological role of
BMP-2 on three novel ovarian cancer cell lines (TOV-
2223, TOV-1946, TOV-112D). These lines were selected
since they do not express detectable levels of BMP-2, con-
sequently, their sensitivity and response to recombinant
BMP-2 protein was examined. The ability of BMP-2 to
induce signaling pathways and expression of target genes
was investigated. Functional assays were also performed
to determine the in vitro behavior of these cell lines in
response to BMP-2 treatment. Finally the association
between BMP-2 and ovarian cancer patient survival was
examined using ovarian cancer tissue array analysis.
Methods
Cell culture and reagents
The TOV-2223, TOV-1946 and TOV-112D cell lines,
developed from long term passages of serous ovarian can-
cer samples as described previously [32,33], were grown at
37°C in 5% CO2 and in OSE consisting of 50:50 medium
199:105 supplemented with 5% fetal bovine serum (FBS)
and 2 μg/ml Gentamicin. All reagents used for cell culture
media were purchased from Wisent (Qc, Canada).
Human recombinant BMP-2 (355-BM-010/CF) and
mouse Noggin (#1967-NG-025/CF) were supplied by
R&D system (Mineapolis, MN, USA). TNF-α was obtained
from Roche Applied Science (Indianapolis, IN). BMP-2-
pCMV6-XL4 was purchased from Origene (Rockville,
MD) and cloned into pcDNA3.1 (Invitrogen Life Technol-
ogies, Carlsbad, CA) as a NotI fragment. The pcDNA3.1-
BMP-2 gene was sequenced to confirm the correct inser-
tion of BMP-2 cDNA in the pcDNA3.1 vector.Journal of Ovarian Research 2009, 2:4 http://www.ovarianresearch.com/content/2/1/4
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Primary cultures, tumor samples and patient 
characteristics
Tumor samples were collected from surgeries performed
at the Centre hospitalier de l'Université de Montréal
(CHUM). An independent pathologist assigned histopa-
thology and tumor grade according to International Fed-
eration of Gynecology and Obstetrics (FIGO) criteria. A
gynecologic oncologist reviewed tumor stage and residual
disease. Normal tissues were obtained from tumor-free
participants that have undergone oophorectomy. Primary
cell cultures from normal ovarian surface epithelia
(NOSE) and EOC samples were established as described
[34,35]. Cells in primary culture were maintained in OSE
media supplemented with 10% (v/v) fetal bovine serum
(FBS), 2.5 ug/mL amphotericin B and 50 μg/mL gen-
tamicin [34]. The tumor samples used for the tissue array
studies are presented in Table 1. Tissue selection criteria
for this study was based on all histopathologies from
chemotherapy-naïve patients having provided informed
consent with all samples having been collected between
1993–2003. Clinical data were extracted from the Système
d'Archivage des Données en Oncologie (SARDO) that
includes entries on tumor grade and stage, treatment and
clinical outcomes such as the progression-free interval as
defined by RECIST criteria and survival. No correlation
between age of embedded paraffin tissues and antibody
staining intensity on the tissue array was identified.
ELISA
Culture supernatants from confluent cellular monolayers
were centrifuged at 3000 rpm for 10 min and frozen at -
80C until further use. All ascites fluids were re-centrifuged
for 10 min at 8000 rpm before performing ELISAs. After
centrifugation, samples were tested by ELISA for secreted
mature BMP-2 (item DBP200, R&D System) concentra-
tion according to the manufacturer's instructions. The
limit of detection for BMP-2 was 30 pg/ml.
RNA preparation and Quantitative PCR
Total RNA from cell lines was prepared using the RNeasy
kit from Qiagen (Qiagen Inc., ON, Canada). The cDNA
synthesis was done according to the protocol of the Super-
Script™ First-Strand Synthesis System for real time PCR
(Invitrogen Life Technologies, Carlsbad, CA) with a start-
ing amount of 2 μg RNA and reverse transcription per-
formed with random hexamers. The PCR reaction was
performed with a Rotor-gene 3000 Real-Time Centrifugal
DNA Amplification System (Corbett tumor tissues
Research, NSW, Australia). The Quantitect™ SYBR Green
PCR (Qiagen) reaction mixture was used according to the
manufacturer's instructions. Serial dilutions were per-
formed to generate a standard curve for each gene tested
in order to define the efficiency of the real time PCR reac-
tion and a melt curve was done to confirm the specificity
of the reaction. Based on the strong stability of ERK1 gene
expression in ovarian cancer tissue, it was chosen as an
internal control [1]. All experiments, including positive
and negative controls, were performed in triplicate. The
PCR primers targeted exonic sequences that were inter-
rupted by at least one intron. The amplicons were
sequenced to verify their specificity for the targeted genes.
Primers were: Id1 fw 5'-cggaatctgagggagaacaag, rev 5'-ctga-
gaagcaccaaacgtga; Smad6 fw 5'-gagctgagccgagagaaaga, rev
5'-agatgcacttggagcgagtt: Snail fw 5'-gagtggttcttctgcgctac, re
v 5'-cagagtcccagatgagcatt; Wnt5a fw 5'-gcgcgaagacaggcatca
aag, rev 3'-ggcgttcaccacccctgctg; Erk1 fw 5'-gcgctggctcac-
ccctacct, rev 5'-gccccagggtgcagagatgtc, BMPR1a fw 5'-cttat-
tcagctgcctgtggt, rev 5'-attcttccacgatccctcct; BMPR1b fw 5'-
tacaagcctgccataagtgaagaagc, rev 5'-tcatcgtgaaacaatatccgtctg
and BMPR2: fw 5'-gctaaaatttggcagcaagc, rev 5'-cttgg gccct
atgtgtcact.
Western blot analysis
Cells were lysed with cold lysis buffer (10 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT/1 mM
NaF/0.5% NP-40/0.5 mM PMSF/0.2 mM sodium
orthovanadate/2 μg/ml of aprotinin, leupeptin and pep-
statin), and the lysate boiled in loading buffer, separated
by SDS-PAGE, and transferred onto a nitrocellulose mem-
brane. Membranes were saturated with 5% (w/v) milk/
PBS/0.1% Tween 20. Immunodetection was done as
described in the ECL kit protocol (Amersham Pharmacia):
Table 1: Composition of the ovarian cancer tissue array
Histopathology Number of samples Low stage High stage Grade 1 Grade 2 Grade 3 LMP
S e r o u s 1 9 3 1 7 6472
E n d o m e t r i o i d 2 5 1 8 6 9841
C l e a r  c e l l 1 5 1 0 5 2283
M u c i n o u s 2 5 2 0 2 1021 9
M i x e d  c e l l s 5 2 3 0041Journal of Ovarian Research 2009, 2:4 http://www.ovarianresearch.com/content/2/1/4
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i.e. incubated 2 h at room temperature with specific anti-
body, washed with PBS and incubated for another 30 min
at room temperature with peroxidase-conjugated anti-
bodies (Santa-Cruz Biotechnology Inc.). Western-blot
analysis was performed with Erk1 (Santa Cruz Biotechnol-
ogy Inc, CA), Smad1/5/8 (A-14 Santa Cruz Biotechnology
Inc.), phospho-Erks (Cell Signaling, Beverly, MA, USA),
phospho-Smad1/5/8 (Cell Signaling), p65 (Santa Cruz
Biotechnology Inc), Akt (Santa-Cruz Biotechnology Inc.),
phospho-Akt and phospho-S-536-p65 (Cell Signaling)
and beta-Actin (AbCam, MA, USA) antibodies. All experi-
ments were performed in triplicate with the TOV-2223
cell line and at least twice for the TOV-1946 and TOV-
112D cell lines.
Cytoplasmic and nuclear extracts
To prepare cellular extracts, 5 × 106 cells were washed
twice in cold PBS buffer and resuspended in lysis buffer
containing 10 mM Tris pH 7.9/10 mM NaCl/5 mM
MgCl2/10 mM sodium orthovanadate/0.5 mM PMSF/10
μg/ml of the protease inhibitors (PMSF, pepstatin, leu-
peptin and aprotinin). After swelling the cells for 30 min
on ice, 0.1% Nonidet P-40 and 10% glycerol (v/v) were
added and the lysates centrifuged for 1 min at 4°C and
5,000 rpm. Supernatants consisting of cytoplasmic
extracts were carefully decanted for cytoplasmic extracts.
Nuclei pellets were resuspended for 1 h in 40 μl of lysis
buffer containing 10 mM Tris pH 7.9/400 mM NaCl/0.1
EDTA/0.5 mM DTT/5% glycerol/0.5 mM PMSF/10 μg/ml
protease inhibitors. Particulate matter was eliminated by
centrifugation for 10 min at 13,000 × g at 4°C. Protein
concentrations were determined using the Bradford
method.
Transfection and luciferase reporter assay
Cells were plated in 96-well plates and at 70–80% conflu-
ence (approximately 5 × 104 cells), they were co-trans-
fected with 0.2 μg of DNA and 200 ng of a constitutively
active Renilla luciferase (pCMV-RL) (Promega, WI, USA)
by the lipofectamine method (Invitrogen Life Technol-
ogy). After 6 h, cells were washed in fresh medium and
incubated overnight. Cells were stimulated for 16 h with
BMP-2 or TNFα and were then assayed for luciferase activ-
ity using the dual luciferase reporter assay system
(Promega). The 3enh-κb-CONA-luc carries a firefly luci-
ferase gene under the control of a trimeric repeat of the κB
consensus [36].
Cell proliferation
To determine the effect of BMP-2 on cell growth, 5 × 104
cells were plated into six well culture plates. After allowing
the cells to adhere overnight they were treated with
recombinant BMP-2 and/or Noggin. Two, four and six
days later, cells were detached with trypsin and counted in
the presence of 0.05% Trypan blue using a hemacytome-
ter. Untreated cells were used as controls.
Migration assays
Cells were grown to confluence in 6 well culture plates.
Using a pipet tip, a wound was produced in the monol-
ayer at two different positions on the plate. The adherent
monolayer was then washed two times in PBS to remove
non-adherent cells and media/FBS was added with or
without BMP-2. After 20 or 40 hrs the open wound surface
area was quantified by digital images taken under phase
contrast microscopy. All experiments were repeated at
least twice.
Spheroid formation
Spheroids were formed using a modification of the hang-
ing droplet method [37]. Briefly, 4 × 103 cells were resus-
pended in 16 μl of OSE/FBS media supplemented with 50
ng/ml BMP-2 and placed on the cover of a 150 mm tissue
culture plate. The cover was placed over a plate that con-
tained 15 ml of OSE to prevent dehydration of the hang-
ing droplets. Spheroid formation was monitored after
four and ten days, and representative spheroids were pho-
tographed. Untreated cells were used as controls.
Tissue array and immunohistochemistry (IHC)
A tissue array containing 94 cores of ovarian epithelial tis-
sues was built (Table 1, [1]). A detailed protocol is
described in Le Page et al, [1]. Briefly, the tissue array was
heated at 60°C for 30 min, de-paraffinized in toluene and
rehydrated in a gradient of ethanol. Antigen retrieval was
done in 90°C citrate buffer (0.01 M citric acid + 500 ul
Tween-20/L adjusted to pH 6.0) (J.T. Baker Philipsburg,
NJ) for 15 min. The tissue was blocked with a serum-free
reagent (DakoCytomation Inc., Mississauga, ON) and
incubated with BMP-2 antibodies (Santa-Cruz Biotech-
nology, CA, USA) overnight at 4°C in a humid chamber.
Optimal antibody concentration was determined by serial
dilutions. Endogenous peroxidase activity was quenched
by treatment with 3% H2O2. The array was incubated with
a secondary biotinylated antibody (DakoCytomation
Inc.) followed by incubation with a streptavidin-peroxi-
dase complex (DakoCytomation Inc.) for 10 min at room
temperature. Reaction products were developed using
diaminobenzidine containing 0.3% H2O2 as a substrate
for peroxidase and nuclei were counterstained with
diluted hematoxylin. Epithelial zones were scored accord-
ing to the intensity of staining (value of 0 for absence, 1
for weak, 2 for moderate, 3 for high and 4 for very high
intensity). Each array was independently analyzed in a
blind study by two independent observers.
Statistical analysis
For survival and progression-free disease analyses, we
used the Cox regression survival model with time depend-
ent covariate and Kaplan-Meier curves coupled with the
log rank test. Receiver operating characteristics (ROC)
curves were generated for each marker to define a thresh-
old of expression corresponding to the best sensitivity andJournal of Ovarian Research 2009, 2:4 http://www.ovarianresearch.com/content/2/1/4
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specificity for patient survival. A threshold of BMP-2
intensity = 4 appeared optimal. For Cox regression analy-
sis, the markers were treated as categorical variables based
on the threshold of expression. All statistical analyses
were performed using SPSS software, version 11.0 (SPSS
Inc., Chicago, IL, USA).
Results
Expression of BMP-2 in epithelial ovarian cancer cells
We have previously observed that BMP-2 expression is up-
regulated in primary cultures of epithelial ovarian cancer
cells and epithelial ovarian cancer tissues as compared to
normal surface epithelial cells (Figure 1A and [1]). In
addition, supernatants of primary cultures of cancerous
cells showed higher concentrations of BMP-2 than super-
natants from NOSE cells (Figure 1B) demonstrating that
an active mature form of BMP-2 is expressed by ovarian
cancer cells and could be release in the microenviron-
ment. To further investigate the expression of BMP-2, we
also compared its mRNA expression in matched malig-
nant ascites cells and solid tumor from the same patient.
As shown in Figure 1C, more than half of the patients
tested showed higher expression of BMP-2 in tumor cells
from ascites compared to tumor cells from solid tumors.
This difference was statistically significant (p = 0.05, t-
test).
BMP-2 activates SMAD 1/5/8 and Erk MAPKs in ovarian 
cancer cell lines
To investigate the role of BMP-2 in ovarian cancer cells we
selected three cell lines, TOV-2223, TOV-1946 and TOV-
112D, for in vitro assays [33]. Microarray and RT-PCR
analyses revealed that, although the three cell lines did
not constitutively express BMP-2, they did express
BMPR1a, BMPR1b and BMPR2 receptors (Table 2). Based
on RNA expression, TOV1946 cells appear to express less
BMPR2 receptor. In contrast the OV90 cell line [32] con-
stitutively expressed BMP-2 but showed a very low expres-
sion of the corresponding receptors. These results
suggested that the three cell lines, TOV-2223, TOV-1946
and TOV-112D could respond to endogenous stimulation
with BMP-2.
To determine whether the BMP-2 signaling pathways were
functional in these cell lines, we examined the effect of
BMP-2 treatment on three main signaling pathways. We
first stimulated cells with BMP-2 and examined the phos-
phorylation and nuclear translocation of Smad1/5/8,
since BMP-2 is thought to predominantly act through the
activation of these transcription factors. The ability of
BMP-2 to phosphorylate Smad1/5/8 was examined by
western-blot using an antibody, which specifically recog-
nizes the phosphorylated forms. As shown in Figure 2A,
phosphorylation of Smad1/5/8 was induced after 20 min-
utes of treatment with as low as 10 ng/ml BMP-2 (Figure
2A). As expected the nuclear translocation of p-Smad1/5/
8 was concomitant to their phosphorylation within the
cytoplasm (Figure 2B). This effect was inhibited in pres-
ence of Noggin. Based on findings with TOV2223, the
A. BMP-2 expression in normal and malignant primary cul- tures Figure 1
A. BMP-2 expression in normal and malignant pri-
mary cultures. RNA expression levels were normalized to 
that of the control RNA by real time RT-PCR assays. Relative 
fold change expression was the ratio of the first EOC sample 
to that of other samples. Values represent the mean +/- SEM 
of two experiments. B. BMP-2 secretion in culture 
media of NOSE or EOC cell primary cultures. Cell-
free supernatants were collected and tested for BMP-2 con-
centration by ELISA. Values represent the mean of duplicate 
experiments. Significance as compared to NOSE samples was 
defined as p < 0.05 using a Student t-test. C. BMP-2 mRNA 
expression in primary cultures of EOC from solid 
tumor and ascites. Expression levels were quantified by 
real time RT-PCR and compared to the control RNA (Erk-1) 
Relative fold change expression was the ratio of the EOC 
from primary tumor sample to that of ascitic sample from 
the same patient. Values represent the mean of two experi-
ments.
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response to BMP-2 in TOV-112D and TOV-1946 cell lines
was tested with the maximal dose of 50 ng/ml BMP-2 (Fig-
ure 2).
BMP-2 has also been shown to induce mitogenic signaling
through the activation of Erk MAPKs [38]. In our ovarian
cancer cell lines, constitutive phosphorylation of Erk
MAPKs was visible and a slight transient increase was
induced in the cytoplasm after 20 min of BMP-2 treat-
ment (Figure 2A). This effect was more evident in the
nuclear compartment and was dose-dependent as well as
inhibited by the presence of Noggin (Figure 2B). Similar
findings were seen in TOV-112D and TOV-1946 cell lines
treated with 50 ng/ml BMP-2 (Figure 2).
Altogether, these results show that BMP-2 can induce a
classical SMAD signaling pathway and that BMP receptors
are functional in the three cell lines used. Consequently,
these cell lines appear to be a good model to study BMP-
2 effects on ovarian cancer cells.
BMP-2 does not activate the Akt/NF-kB pathway
BMP-2 was also suspected to induce NF-kappaB (NF-κB)
activation through the TAK1 and Akt pathways [29]. To
determine if BMP-2 stimulation leads to NF-κB activation
through the Akt pathway in ovarian cancer cell lines, we
examined the phosphorylation of Akt and p65 using a
specific antibody that recognizes phosphorylated serine
sites. Neither constitutive nor BMP-2 induced phosphor-
ylation of Akt was observed in TOV-2223 cells (Figure 2C)
despite varying experimental conditions and film expo-
sures. A weak and constitutive phosphorylation of Akt was
seen in TOV-112D (not shown) and TOV-1946 (Figure
2C) cells but this basal level did not increase following
BMP-2 treatment. Similarly, no constitutive or BMP-2
induced p65 phosphorylation was observed in TOV-2223
(not shown). While a weak constitutive phosphorylation
of p65 was observed in TOV-112D cells, no increased
phosphorylation was detected after 20 min of BMP-2
Table 2: Gene expression of BMP receptors in ovarian cancer 
cell lines.
Gene/Cell line TOV-112D TOV-1946 TOV-2223
BMPR1a 6.40 0.28 3.46
BMPR2 25.10 0.11 1.0
BMPR1b 3.81 3.14 92.4
RNA was extracted, retro-transcribed and used for real-time PCR 
using specific primers for BMPR1a; BMPR1b; BMPR2
Modulation of Smad, ERK, Akt and NF-κB activation by BMP- 2 Figure 2
Modulation of Smad, ERK, Akt and NF-κB activation 
by BMP-2. A and B. TOV-2223 cells were stimulated in 
complete media for indicated times with 50 ng/ml BMP-2 
(left) or for 20 min with increasing doses of BMP-2 (10, 50 or 
100 ng/ml). TOV-112D and TOV-1946 cells were stimulated 
for 20 min with 50 ng/ml BMP-2. Cytoplasmic (EC) or 
nuclear (EN) extracts were subjected to western-blotting 
using anti-phosphoserine Smad1/5/8 and anti-phospho-tyro-
sine Erk1/2 antibodies. *Cells were stimulated with 50 ng/ml 
BMP-2 and 0.5 ng/ml Noggin C. Total extracts were sub-
jected to western-blotting using anti-phosphoserine 473 Akt. 
TOV-2223 cells were stimulated for 5 or 20 min with 50 ng/
ml BMP-2. TOV-1946 cells were stimulated with 50 ng/ml 
BMP-2 for 20 min. D. Total extracts from TOV-2223 cells 
were immunoprecipitated with anti-p65 antibody and loaded 
on an 8% polyacrylamide gel. Western-blotting was per-
formed with anti-phosphoserine 536 p65. E. Cells were 
cotransfected with Renilla and 3κB-conA-luc vectors. Eight 
hours after transfection, cells were incubated with fresh 
media in the presence or absence of 50 ng/ml BMP-2 with or 
without 0.5 ng/ml Noggin or 10 ng/ml TNFα for 24 hrs. Cells 
were assayed for luciferase activity. Relative firefly luciferase 
activity was the ratio of luciferase activity in treated cells to 
that of non-treated cells. All experiments were repeated 
three times with similar results.Journal of Ovarian Research 2009, 2:4 http://www.ovarianresearch.com/content/2/1/4
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treatment (Figure 2D). To further confirm the absence of
NF-κB activation by BMP-2, we examined the transcrip-
tional activity of NF-κB following BMP-2 treatment. TNFα
stimulation was used as a positive control. The transcrip-
tional activity of NF-κB was measured by transient trans-
fection of a reporter plasmid carrying a κB dependent
promoter linked to a luciferase gene. After performing
luciferase assays, no increases in κB dependent luciferase
activity was observed in any of the cell lines tested (Figure
2E).
BMP-2 increases Id1, Smad6 and Snail expression in 
ovarian cancer cell lines
We next examined whether the signaling pathways acti-
vated by BMP-2 led to the expression of known target
genes of Smad such as ID1 and SMAD6. Since BMP-4
shares the same receptor with BMP-2, BMP4 may show
effects similar to those seen with BMP-2, and therefore we
also examined Snail expression, a BMP-4 regulated gene in
ovarian cancer cells [26]. Real time RT-PCR analyses of
each target gene showed that BMP-2 treatment increased
Id1, Snail  and Smad6  mRNA expression approximately
two-fold (Figure 3). Time course experiments revealed
that SNAIL expression was more transient than the induc-
tion of ID1 or SMAD6 expression.
A further increase in mRNA expression was not observed
with doses higher than 10 ng/ml BMP-2. BMP-2 increased
Id1, Snail and Smad6 expression in assays with TOV-223
and TO1946 cell lines but with slightly different kinetics
than those seen with the TOV-2223 cell line. The largest
fold change was observed in assays with TOV-1946 cells,
which expressed the lowest constitutive level of Id1, Snail
and Smail6 mRNA (data not shown). Wnt5a gene expres-
sion was used as negative control for gene expression
assay as Wnt5a is not known to be regulated by BMPs.
Indeed, q-RT-PCR showed that BMP-2 did not affect the
expression of this gene confirming that the effect of BMP-
2 on Snail, Smad6 and Id1 expression is specific to BMP-2
stimulation.
BMP-2 affects the proliferation of ovarian cancer cell lines
We examined whether BMP-2 affects cellular proliferation
of ovarian cancer cells. As seen in Figure 4A, BMP-2
decreased the cellular proliferation rate of TOV-2223 cells
in a dose dependent manner. This effect was inhibited by
the presence of Noggin. However the growth of either
TOV-112D or TOV-1946 cell lines was not significantly
affected by doses of 50 ng/ml BMP-2 or higher (Figure 4A)
(data not shown).
BMP-2 increases cellular migration of ovarian cancer cell 
lines
Cell migration in response to BMP-2 was estimated by the
wound assays after 20 or 40 hours of treatment. The pres-
ence of BMP-2 in the culture media of TOV-2223 cells
increased their motility in a dose dependent manner with
a maximum effect being observed after 40 hrs of treatment
with 100 ng/ml BMP-2 (Figure 4B). In TOV-112D and
TOV-1946, a similar effect was observed after only 20 hrs
of treatment with 50 ng/ml BMP-2 (Figure 4B).
Effect of BMP-2 on spheroid formation
We have previously demonstrated that the TOV-112D and
TOV-1946 cells are able to grow as spheroids as opposed
to TOV-2223 [33]. Since the relationship between these
three-dimensional structures and migration remains
poorly defined, we determined the effect of BMP-2 on the
formation of in vitro spheroids. For this purpose the cell
lines were incubated either in the absence or presence of
50 ng/ml BMP-2. The formation of spheroids was deter-
mined after four and ten days. As expected, the TOV-2223
cells were not able to form compact spheroid and the
presence of BMP-2 did not affect the spheroid formation
(Figure 4C). In contrast, we noted significantly more cell
scattering in the TOV-112D and TOV-1946 spheroids after
treatment with BMP-2 (Figure 4C).
BMP-2 is associated with a poor prognosis in ovarian 
cancer patients
We analyzed the association between patient outcome
and BMP-2 protein expression by immunohistochemistry
(IHC) using a tissue microarray of clinical samples from
89 ovarian cancer patients (Table 1 and Table 3) that was
Gene expression induced by BMP-2 Figure 3
Gene expression induced by BMP-2. Cells were treated 
with 50 ng/ml BMP-2 in complete media or with indicated 
doses for 90 min. Where indicated, 0.5 ng/ml Noggin (N) 
was used. RNA was extracted, retro-transcribed and used 
for real-time PCR using specific primers for Id1, Smad6, Snail 
or Wnt5a. Relative fold change expression was the ratio of 
treated cells to that of non-treated cells. Values are the mean 
+/- SEM of duplicate wells from at least two independent 
experiments. * p < 0.05 (Student t-test).
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previously used to determine the potential of BMP-2 as a
tumor marker [1]. Analysis of this tissue array showed that
BMP-2 expression did not significantly correlate with age,
stage or residual disease of patients. However, BMP-2
staining positively correlated with tumor grade (r = 0.25,
p = 0.02, Spearman test). Kaplan Meier and Cox regres-
sion analyses also showed that BMP-2 expression was sig-
nificantly associated with shorter survival period (p =
0.029 log rank) (Figure 5A) and with a high hazard ratio
(HR = 3.475, 1.054–11.453). Since clinically low stage (I–
II) disease has better outcomes that later stage (III–IV) dis-
ease, we also re-analyzed the data based on this stratifica-
tion. Within low stage patients, BMP-2 was not associated
with survival (p = 0.342, log rank) in contrast to high stage
patients where there was significant association (p =
0.037, HR = 5.851, 1.112–30.787) (Figure 5B).
Discussion
In this study we attempted to clarify the role of BMP-2 in
ovarian cancer. An initial report highlighted the overex-
pression of BMP-2 in primary cultures of ovarian cancer
cells and in the tissues of ovarian cancer patients [1].
Using three different cell lines, we report different in vitro
and in vivo effects of BMP-2 on epithelial ovarian cancer
cells. The three cell lines selected for this study expressed
receptors for BMP-2 and were responsive to BMP-2 stimu-
lation as seen by the activation and phosphorylation of
Smad1/5/8 transcription factors as well as the gene expres-
sion of Id1, Snail and Smad6. However, although the sign-
aling pattern was similar in all cell lines, they did not
show the same biological activities in the presence of
BMP-2. Only the TOV-2223 cell line showed a reduce pro-
liferation rate in the presence of BMP-2 and was not influ-
enced when cultured in 3D spheroid conditions. In
contrast, the motility of all cell lines was stimulated in
presence of BMP-2. Further work needs to be done to
define particular characteristic of each ovarian cancer cell
line that determine response to BMP-2. These results sug-
gest that the effects of BMP-2 on ovarian cancer cells may
be complex and dependent on the particular cellular con-
text. The heterogeneity in response to BMP-2 is unlikely
related to the histopathological subtype since TOV-2223
and TOV-1946, which respond differently to the presence
of BMP-2, are both derived from a serous subtype.
Similar effects with BMP-4, as observed here with BMP-2,
have recently been reported in ovarian cancer cell lines
and ovarian cancer primary cultures [26,39]. We observed
that BMP-2 slightly reduced the proliferation of TOV-
2223 cells but had no effect on TOV-112D and TOV-1946
Effects of BMP-2 on proliferation, migration and spheroid  formation Figure 4
Effects of BMP-2 on proliferation, migration and 
spheroid formation. A. Cells were treated in complete 
media with indicated doses as indicated or with 50 ng/ml 
BMP-2 or left untreated for four days. Cells were counted 
every two days and media was changed every second day. 
Values are the mean +/- SEM of duplicate wells from at least 
two independent experiments. B. BMP-2 increases the motil-
ity of cells. Wounds were made on confluent monolayers of 
cells and then treated at indicated doses or with 50 ng/ml 
BMP-2. After 20 hrs (TOV-2223) or 40 hrs (TOV-112D and 
TOV-1946) the open wound surface area was quantified by 
digital images taken under a phase contrast microscope. Val-
ues are the mean +/- SEM of duplicates in at least two exper-
iments and represent the percentage of total area covered by 
the cells in each image. C. Effect of BMP-2 on spheroid for-
mation. Cells were cultured using a modification of the hang-
ing droplet method. Cells were incubated in media with or 
without 50 ng/ml BMP-2. Spheroid formation was monitored 
after ten days. Arrows show scattered cells. All pictures 
were taken at a magnification of 100×. For all figures * p < 
0.05, ** p < 0.10. (Student t-test).Journal of Ovarian Research 2009, 2:4 http://www.ovarianresearch.com/content/2/1/4
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cells suggesting that some cell lines are resistant to the
anti-proliferative activity of BMP-2. In the same way,
BMP-4 has also been reported to slightly reduce the prolif-
eration of SKOV3 ovarian cancer cells, as well as some pri-
mary cultures of ovarian cancer cells while other ovarian
primary cultures were not sensitive to this protein [39].
The reason why some ovarian cancer cells are resistant to
this anti-proliferative effect is unknown. We also observed
similar increases in motility in cells treated with BMP-2 as
reported by others with BMP-4 [26]. Since BMP-2 and
BMP-4 bind the same type I and type II BMP receptors, it
is not surprising to notice similarities in their induction of
signaling pathways. A strategy based on the single inhibi-
tion of either BMP-2 or BMP-4 may not be sufficient to
reduce the tumorigenic effect driven by Smad1/5/8 signal-
ing. In contrast, targeting several BMPs by the use of extra-
cellular antagonists such as Chordin, Noggin or Gremlin
may be more effective. Preliminary results shown here
with Noggin and by others using Noggin [26] and Chor-
din [31] support the potential therapeutic role of these
antagonists in ovarian cancer progression through the
inhibition of BMP signaling. It will be of great interest to
test Noggin, Chordin, Cerberus or Gremlin as in vivo
potential tumor suppressors in xenograph models.
We also observed that some malignant cells from ascites
samples overexpressed BMP-2 compared to cells from
solid tumor samples of the same patients. The motility of
cancer cells is an important factor determining the meta-
static spread of tumors. As ascites tumor cells are detached
from the primary tumor site and may have acquired a
metastatic potential, this observation suggests that BMP-2
may be associated or involved in the process of evading
tumor cells from the primary site to the omentum. In line
with this hypothesis, we observed that BMP-2 stimulates
the in vitro migration of ovarian cancer cell lines. In addi-
tion several reports have shown a role of BMP-2 in inva-
sion of lung, prostate, breast cancer cells and BMP-4 in
ovarian cancer [21,40,41]. To confirm the role of BMP-2
in the metastatic process of ovarian cancer cells, addi-
tional in vivo assays would be required. Metastasis is a
major cause of cancer related mortality. The fact that
patients with higher expression of BMP-2 in ovarian tis-
sues have shorter survival supports a role for BMP-2 in the
motility of ovarian cancer cells and aggressiveness of ovar-
ian tumors. Further functional assays are required to
determine the exact role of BMP-2 in these biological
processes.
Conclusion
In conclusion, the evidence provided in this study support
the fact that BMP-2 overexpression may modulate cellular
motility and cellular adherence. In addition, we show that
high expression of BMP-2 in ovarian cancer tissues is asso-
ciated with shorter survival in patients.
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